Table 1.

Therapeutic strategies to overcome heterogeneity of tumor immune microenvironment

Strategies	Regimen	Condition	Trial ID
Targeting common antigen	CD19 CAR-T	B-lineage NHL	NCT03029338, NCT02030834
	EGFR CAR-T	Lung, liver, stomach	NCT03179007, NCT03525782
	Mesothelin CAR-T	Ovarian, cervical, pancreatic, lung	NCT01583686
	Muc-1 CAR-T	Advanced solid tumors	NCT03179007, NCT03525782
	EpCAM CAR-T	Colon, pancreatic, prostate, gastric, liver	NCT03013712
	GD2 CAR-T	Glioblastoma	NCT04099797
	CEA CAR-T	Multiple tumor types	NCT02349724
	Glypican-3 CAR-T	Liver	NCT02932956
	DLL-3 CAR-T	Lung	NCT03392064
	Gp100 CAR-T	Melanoma	NCT03649529
	MAGE-A10 TCR-T	NSCLC	NCT02592577
	NY-ESO-1 TCR-T	Ovarian, melanoma, NSCLC	NCT01567891, NCT01350401, NCT02588612
	AFP TCR-T	Liver	NCT03132792
	MAGE-A3 TCR-T	Advanced solid tumors	NCT02153905
	WT1 TCR-T	Mesothelioma, NSCLC	NCT02408016
	HPV-16 E7 TCR-T	HPV-associated tumors	NCT02858310
	MART-1 TCR-T	Melanoma	NCT00706992
	EBV LMP2 TCR-T	NPC	NCT03925896
Prevailing with a multi-targeting strategy	Sequential CD19, CD20 CAR-T	B-lineage NHL	NCT03207178
	CD19-CD20 dual CAR-T	B-lineage NHL	NCT03398967, NCT03019055
	CD19-CD22 dual CAR-T	B-lineage NHL	NCT03593109, NCT-3468153, NCT03233854
Boosting immunogenic cell death and epitope spreading	T-VEC + pembrolizumab	Head and neck squamous cell carcinoma	NCT02626000
	HF-10 + ipilimumab	Melanoma	NCT02272855
	ONCOS-102 + cyclophosphamide	Advanced solid tumors	NCT01598129
	ONCOS-102 + pembrolizumab	Melanoma	NCT03003676
	OBP-301 + pembrolizumab	Advanced solid tumors	NCT03172819
	NeoVax + ipilimumab	Melanoma	NCT03929029
	PGV001 + Poly-ICLC	Advanced solid tumors	NCT02721043
	AutoSynVax + QS-21	Advanced solid tumors	NCT02992977
	mRNA-4157	Advanced solid tumors	NCT03313778
	Radiotherapy + ipilimumab	Melanoma	NCT01449279
	Radiotherapy + immature dendritic cells	Advanced solid tumors	NCT00278018
	Microwave ablation	Liver	NCT02851784